ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Purpose: Current cervical cancer treatments have yet to realize significant advances in patient quality of life. To overcome the challenges of off-target toxicity and inefficient delivery, we developed targeted ROS-responsive selenium nanoparticles, based on selenium's anticancer properties. Methods: FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models. Results: Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity. Conclusion: This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway
- Date Crossref
- 01/02/2026
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nanchang University pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Jiangxi Medical College The First Affiliated Hospital pays non établi dans la noticeÉtablissement de santé
-
Ningbo Medical Center Lihuili Hospital pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of Nanchang University pays non établi dans la noticeÉtablissement de santé
-
Ningbo University Ningbo Institute of Innovation for Combined Medicine and Engineering (NIIME) pays non établi dans la noticeUniversité ou école supérieure
-
School of Materials Science and Chemical Engineering pays non établi dans la noticeUniversité ou école supérieure
Nanchang University, The First Affiliated Hospital — First Affiliated Hospital of Jiangxi Medical College et Ningbo Medical Center Lihuili Hospital, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.